Biogen BIIB Reportable Segment — Other segment expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's reportable segment — other segment expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's reportable segment — other segment expense?
- Biogen (BIIB) reported reportable segment — other segment expense of $317M in Q1 2026.
- How has Biogen's reportable segment — other segment expense changed year-over-year?
- Biogen's reportable segment — other segment expense decreased by 10.4% year-over-year, from $353.9M to $317M.
- What is the long-term trend for Biogen's reportable segment — other segment expense?
- Over 3 years (2022 to 2025), Biogen's reportable segment — other segment expense has grown at a 91.9% compound annual growth rate (CAGR), from $213.5M to $1.51B.
- What does reportable segment — other segment expense mean?
- This captures miscellaneous operational costs associated with the segment that are not classified as R&D or SG&A, such as restructuring charges, impairment losses, or specific collaboration-related expenses. It provides insight into non-recurring or peripheral operational burdens affecting segment profitability. Monitoring this helps identify hidden costs that impact the bottom line.